VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, effective immediately, signaling a strategic move to bolster its financial leadership as it advances its proprietary BiTAC oncology pipeline. Willener, who brings more than 30 years of international experience spanning investment banking, corporate finance, asset management, and capital markets, will report directly to Chief Executive Officer and co-founder Christoph Antz, Ph.D. (https://ibn.fm/Eibml).
The appointment comes at a critical juncture for VERAXA, which is developing innovative cancer therapies based on its BiTAC platform, with a pipeline centered on antibody-drug conjugates (ADCs) and T-cell engagers. The company has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform, underscoring the potential of its approach to targeted cancer treatment.
Willener’s extensive career across the United States, Europe, and Asia includes a recent role as director of corporate development at Exentis Group AG, where he gained further experience in strategic leadership. His deep expertise in capital markets and corporate finance is expected to be instrumental as VERAXA seeks to fund and advance its clinical programs, particularly in the competitive oncology space where ADCs and T-cell engagers are drawing significant attention.
The timing of Willener’s appointment highlights VERAXA’s focus on financial strategy as it transitions from early-stage research toward clinical development. With a proven track record in investment banking and asset management, Willener is well-positioned to guide the company through potential capital raises, partnerships, or other financial maneuvers necessary to bring its therapies to patients. His international background may also aid in forging global collaborations, a key factor in the biotech industry.
VERAXA’s BiTAC platform represents a novel approach to cancer therapy, combining the specificity of antibody-drug conjugates with the immune-activating power of T-cell engagers. The in-vitro proof of concept for BiTAC-ADC suggests that the technology can effectively target and kill cancer cells, a promising sign for future development. As the company moves forward, the addition of a CFO with Willener’s caliber could accelerate progress and enhance investor confidence.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
For full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published, please visit https://IBN.ai/Disclaimer.
